Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback